Abstract
Rheumatic diseases, such as rheumatoid arthritis (RA), osteoarthritis (OA), and spondyloarthritis (SpA), present diagnostic and management challenges due to their impact on connective tissues and the musculoskeletal system. Traditional imaging techniques, including plain radiography, ultrasounds, computed tomography, and magnetic resonance imaging (MRI), play a critical role in diagnosing and monitoring these conditions, but face limitations like inter-observer variability and time-consuming assessments. Recently, deep learning (DL), a subset of artificial intelligence, has emerged as a promising tool for enhancing medical imaging analysis. Convolutional neural networks, a DL model type, have shown great potential in medical image classification, segmentation, and anomaly detection, often surpassing human performance in tasks like tumor identification and disease severity grading. In rheumatology, DL models have been applied to plain radiography, ultrasounds, and MRI for assessing joint damage, synovial inflammation, and disease progression in RA, OA, and SpA patients. Despite the promise of DL, challenges such as data bias, limited explainability, and the need for large annotated datasets remain significant barriers to its widespread adoption. Furthermore, human oversight and value judgment are essential for ensuring the ethical use and effective implementation of DL in clinical settings. This review provides a comprehensive overview of DL's applications in rheumatologic imaging and explores its future potential in enhancing diagnosis, treatment decisions, and personalized medicine.